№ lp_1_2_60224
File format: docx Character count: 57537 File size: 293 KB
This document is a submission for the inclusion of a 2-dose schedule for the 9-valent HPV vaccine (9vHPV) for males and females aged 12-13 years as part of the National Immunisation Program (NIP).
Year: 2015
Region / City: Australia
Topic: Immunization, HPV Vaccine
Document Type: Health Policy
Organization / Institution: Pharmaceutical Benefits Advisory Committee (PBAC)
Author: PBAC
Target Audience: Health professionals, policymakers, researchers
Period of validity: Ongoing from 2015
Date of approval: June 29, 2015
Date of amendments: January 2017
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Inactivated trivalent influenza vaccine (Split Virion) suspension for injection, 180mcg single dose in 0.5mL, Fluzone High-Dose, Australia, 2017–2018
Year: 2017
Country: Australia
Vaccine type: Inactivated trivalent influenza vaccine (TIV-HD)
Manufacturer: Sanofi-Aventis Australia Pty Ltd
Product form: Suspension for injection, 180mcg single dose in 0.5mL
Regulatory approval: TGA registration December 2017
Target population: Persons aged 65 years and older
Purpose: Listing on National Immunisation Program (NIP)
Comparative analysis: Cost-minimisation versus standard quadrivalent influenza vaccine (QIV)
Advisory review: PBAC and ATAGI evaluation
Implementation considerations: Cold chain capacity, provider communication, monitoring adverse events
QUADRIVALENT INFLUENZA VACCINE, Pre-filled syringe, 0.5mL, Afluria® Quad, Seqirus
Year: 2016
Region / City: Australia
Topic: Influenza Vaccination
Document Type: Regulatory Submission
Organ / Institution: PBAC, TGA
Author: Seqirus
Target Audience: Healthcare professionals, regulatory bodies
Period of Validity: Not specified
Approval Date: Not specified
Amendment Date: Not specified
Clinical Trials: Yes
Main Comparator: Fluarix® Tetra
Outcome: Non-inferiority of Afluria® Quad
Context: The document outlines the submission and evaluation of Afluria® Quad for listing on the National Immunisation Program in Australia, comparing it with existing vaccines.
Topics: 9-Valent Gardasil 05mL